AU8494601A - Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV - Google Patents

Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV

Info

Publication number
AU8494601A
AU8494601A AU8494601A AU8494601A AU8494601A AU 8494601 A AU8494601 A AU 8494601A AU 8494601 A AU8494601 A AU 8494601A AU 8494601 A AU8494601 A AU 8494601A AU 8494601 A AU8494601 A AU 8494601A
Authority
AU
Australia
Prior art keywords
prodrugs
hiv
cancer
treatment
acid derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU8494601A
Other languages
English (en)
Inventor
John M Pezzuto
Jerome W Ii Kosmeder
Ze-Qi Xu
Nian En Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Life Sciences Inc
University of Illinois at Urbana Champaign
University of Illinois System
Original Assignee
Advanced Life Sciences Inc
University of Illinois at Urbana Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Life Sciences Inc, University of Illinois at Urbana Champaign, University of Illinois System filed Critical Advanced Life Sciences Inc
Publication of AU8494601A publication Critical patent/AU8494601A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU8494601A 2000-08-18 2001-08-15 Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV Pending AU8494601A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22653600P 2000-08-18 2000-08-18
PCT/US2001/025581 WO2002016395A1 (en) 2000-08-18 2001-08-15 Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv

Publications (1)

Publication Number Publication Date
AU8494601A true AU8494601A (en) 2002-03-04

Family

ID=22849310

Family Applications (2)

Application Number Title Priority Date Filing Date
AU8494601A Pending AU8494601A (en) 2000-08-18 2001-08-15 Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV
AU2001284946A Ceased AU2001284946B2 (en) 2000-08-18 2001-08-15 Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001284946A Ceased AU2001284946B2 (en) 2000-08-18 2001-08-15 Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV

Country Status (9)

Country Link
US (3) US6569842B2 (enExample)
EP (1) EP1309605A1 (enExample)
JP (1) JP2004517045A (enExample)
AU (2) AU8494601A (enExample)
CA (1) CA2418479C (enExample)
NO (1) NO20030748L (enExample)
NZ (1) NZ524087A (enExample)
WO (1) WO2002016395A1 (enExample)
ZA (1) ZA200301269B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943260B2 (en) * 2002-02-02 2005-09-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for obtaining betulinic acid
WO2004018478A2 (en) * 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
EP1594885B8 (de) * 2003-02-11 2009-03-25 Novelix Pharmaceuticals, Inc. Medikament zur wachstumsinhibierung von tumoren
WO2004085459A1 (en) 2003-03-24 2004-10-07 Sterix Limited Oestrogen derivatives as inhibitors of steroid sulphatase
CA2534342C (en) * 2003-07-29 2016-05-10 V. Ravi Chandran Amino acid prodrugs
US20060019934A1 (en) * 2004-05-20 2006-01-26 Saxena Brij B Anti-HIV-1 activity of betulinol derivatives
AU2004322123B2 (en) * 2004-08-02 2009-08-13 Ambrilia Biopharma Inc. Lysine based compounds
US8088757B2 (en) * 2004-09-10 2012-01-03 Biorings Llc Betulinol derivatives as anti-cancer agents
AR051475A1 (es) * 2004-11-05 2007-01-17 Merck & Co Inc Procedimiento para acido{3- [2 (r) -[(1r) - 1-[ 3,5- bis( trifluorometil)- fenil] etoxi] -3 (s) - (4- fluorfenil) morfolin -4- il]metil -5-oxo-4,5-dihidro- [1,2,4]-triazol-1-il} fosfonico
JP4810642B2 (ja) * 2004-11-30 2011-11-09 秋田県 癌転移抑制用トリテルペン誘導体及び該トリテルペン誘導体を用いた癌転移抑制用組成物
WO2006105356A2 (en) * 2005-03-29 2006-10-05 Regents Of The University Of Minnesota Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid
US20070111936A1 (en) 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
AU2006333084A1 (en) * 2005-12-16 2007-07-12 Panacos Pharmaceuticals, Inc. Preparation of pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
US20110152229A1 (en) * 2006-11-22 2011-06-23 Duke University Betulinic acid derivatives as anti-hiv agents
EP2178376A4 (en) * 2007-08-03 2011-12-14 Advanced Life Sciences Inc LUPANIC TRITERPENOIDS MODIFIED IN 30-POSITION AND ITS ANALOG
EP2303280A2 (en) * 2008-05-30 2011-04-06 Novelix Pharmaceuticals, Inc. Compositions and methods for treatment of inflammation and hyperkeratotic lesions
US8372808B2 (en) * 2008-10-31 2013-02-12 Wisconsin Alumni Research Foundation Suppression of glial fibrillary acidic protein
WO2010068668A1 (en) * 2008-12-10 2010-06-17 Advanced Life Sciences, Inc. 23-substituted derivatives of lupane-type pentacyclic triterpenoids
RU2551647C2 (ru) * 2012-11-12 2015-05-27 Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук Трифенилфосфониевые соли лупановых тритерпеноидов, способ получения и применение в качестве противоопухолевых веществ
KR101531821B1 (ko) * 2013-11-27 2015-06-24 주식회사 휴메딕스 페길레이션된 베튤린 유도체를 포함하는 경구 투여용 항암제 조성물
CN107011406A (zh) * 2016-01-28 2017-08-04 思路迪（北京）医药科技有限公司 一种具有抗肿瘤作用的化合物及其制备方法和应用
CA3075729A1 (en) 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. Use of oleandrin to treatn viral infection
JP7370966B2 (ja) 2017-09-14 2023-10-30 フェニックス・バイオテクノロジー・インコーポレイテッド 神経学的状態を治療するための方法および改善された神経保護組成物
AU2019292599B2 (en) 2018-06-29 2022-03-03 Dfh Therapeutics Triterpene amine derivatives
WO2020124043A1 (en) * 2018-12-13 2020-06-18 Gordon Erlinda M Methods of exploiting oncogenic drivers along the human cyclin g1 pathway for cancer gene therapy
SG11202105728YA (en) 2020-03-31 2021-11-29 Phoenix Biotechnology Inc Method and compositions for treating coronavirus infection
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2683531B1 (fr) * 1991-11-13 1993-12-31 Rhone Poulenc Rorer Sa Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2705097B1 (fr) * 1993-05-11 1995-08-04 Rhone Poulenc Rorer Sa Nouveaux dérivés du lupane, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5658947A (en) 1995-03-21 1997-08-19 Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma using betalinic acid
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
JPH0987156A (ja) * 1995-09-19 1997-03-31 Pola Chem Ind Inc 光老化防止剤及び皮膚化粧料
US5804575A (en) 1997-03-27 1998-09-08 The Board Of Trustees Of The University Of Illinois Methods of manufacturing betulinic acid
US6048847A (en) * 1997-09-30 2000-04-11 Dabur Research Foundation Use of betulinic acid and its derivatives for inhibiting cancer growth and a method of monitoring this
US6670345B1 (en) * 1997-09-30 2003-12-30 Dabur Research Foundation Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid
DE69832363D1 (de) * 1998-03-18 2005-12-22 Dabur Pharma Ltd Betulinsauer Derivate zur Hemmung von Krebswachstum
KR20010080507A (ko) 1998-11-18 2001-08-22 추후보정 신규한 베툴린산 유도체, 그의 제조 방법 및 암 성장억제제로서의 그의 용도
AU4331700A (en) * 1999-04-07 2000-10-23 Virginia Commonwealth University Anti-tumor activity of vitamin e, cholesterol, taxol and betulinic acid derivatives
WO2002009719A1 (en) 2000-07-31 2002-02-07 The Nisshin Oillio, Ltd. Antitumor agents

Also Published As

Publication number Publication date
AU2001284946B2 (en) 2007-02-01
US6569842B2 (en) 2003-05-27
NO20030748L (no) 2003-04-15
US7091195B2 (en) 2006-08-15
ZA200301269B (en) 2003-11-03
CA2418479C (en) 2007-12-18
JP2004517045A (ja) 2004-06-10
US20030186945A1 (en) 2003-10-02
EP1309605A1 (en) 2003-05-14
US20020052352A1 (en) 2002-05-02
NZ524087A (en) 2004-08-27
US20070072835A1 (en) 2007-03-29
CA2418479A1 (en) 2002-02-28
WO2002016395A1 (en) 2002-02-28
NO20030748D0 (no) 2003-02-17

Similar Documents

Publication Publication Date Title
ZA200301269B (en) Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV.
AU6147401A (en) Compositions and methods for the treatment of cancer
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU6048201A (en) Quinazoline derivatives for the treatment of tumours
PL362711A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
IL193404A0 (en) Process for the preparation of dihydroxy esters and derivatives thereof
IL150742A0 (en) Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
AU2165102A (en) Pyrazole derivatives for the treatment of viral diseases
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU2001265253A1 (en) Treatment of hiv using hyperthermia
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
GB0000113D0 (en) The use of triazolo-pyridazine derivatives for treating premenstrual syndrome
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
AU2184202A (en) Imidazolone derivatives for the treatment of viral diseases
AU2001282410A1 (en) N-benzylindole-3-acetic acid derivatives for use in the treatment of drug resistan cancer
AU2002246727A1 (en) In situ generation allicin for the treatment of cancer and infectious diseases
AU8679801A (en) Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
AU2002234748A1 (en) Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment
HK1051687A (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
GB9910545D0 (en) The treatment of acarids
AUPQ902000A0 (en) Pharmaceutical composition for the treatment of skin conditions
GB0008161D0 (en) Treatment of cancer